FinVector

About:

FinVector is a world leader in the research and development of Viral-Based Gene Therapy products.

Website: http://www.finvector.com/

Top Investors: Nordic Investment Bank

Description:

FinVector is a world leader in the research and development of Viral-Based Gene Therapy products. Their state-of-the-art facilities, highly experienced scientific team and commitment to work closely with clients every step of the way, have helped us to build an excellent reputation in the gene therapy market. They are authorised under EMA for the production of gene therapy products for clinical and commercial supply.

Total Funding Amount:

45M EUR

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Kuopio, Eastern Finland, Finland

Founded Date:

1993-01-01

Founders:

Number of Employees:

101-250

Last Funding Date:

2023-06-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai